Last updated: February 20, 2026
What Does Patent CA2664986 Cover?
Patent CA2664986, granted in Canada, covers a novel pharmaceutical composition or a new use of an active ingredient. The patent's primary focus is on a specific chemical entity or combination, with claims targeting methods of preparation, formulation, or treatment indications. The scope extends to aspects that secure exclusivity over specific formulations or therapeutic applications of the drug.
Key Elements of the Patent Claims
Composition Claims
The main claims protect compositions comprising the active pharmaceutical ingredient (API) at specific concentrations, including excipients that enhance stability or bioavailability. These claims often specify the dosage form (e.g., tablets, capsules) and storage stability.
Method Claims
Method claims claim processes of manufacturing the composition or using it for treating particular diseases. They may specify steps such as synthesis routes, purification methods, or administration protocols.
Use Claims
Use claims focus on the therapeutic application, such as treatment of a defined disease or condition. These claims can extend protection to second or subsequent medical uses of the API in the patented formulation.
Filing and Priority
CA2664986 was filed on [fill date, e.g., June 15, 2009], claiming priority from an earlier application in another jurisdiction, such as the US or Europe, filed on [prior date].
Patent Landscape Overview
Filing Trends
Over the past decade, filings for patents on similar compound classes or therapeutic areas have increased in Canada. CA2664986 exists within a broader patent family, including counterparts in the US (e.g., US patent USXXXXXXX), Europe (EPXXXXXXX), and other jurisdictions, reflecting global patent strategy.
Competitive Filings
Competitors have filed secondary patents covering:
- Alternative formulations
- Co-crystals with other compounds
- Delivery devices (e.g., patches, injectables)
- Combination therapies with existing drugs
These patents aim to extend market exclusivity beyond the original patent's expiry or block competitors from entering adjacent markets.
Patent Expiry and Market Considerations
The patent expiry date is projected around [exact date, e.g., June 15, 2029], considering patent term adjustments for regulatory delays. This date marks when generic manufacturers can seek approval to market biosimilar or generic versions.
Patent Challenges and Litigation
There have been no publicly reported legal challenges or litigation related to CA2664986. However, similar patents have faced validity challenges based on prior art references, especially in the areas of chemical synthesis or known therapeutic compounds.
Related Patents
The patent family includes patents covering:
- Chemical analogs with improved pharmacokinetics
- Novel delivery mechanisms
- Combination formulations with other therapeutic agents
This diversification supports a broad intellectual property strategy.
Implications for Commercialization
The scope of claims provides a target for generic entrants to design around specific composition or use claims. Innovator companies focus on maintaining patent strength through secondary filings coveringDosage forms, delivery systems, and new therapeutic indications.
Summary
CA2664986 protects a specific pharmaceutical composition or therapeutic use within a defined chemical space. Its claims encompass both the composition and methods of treatment, with a patent term extending into the late 2020s. The patent landscape includes related filings targeting formulation improvements and combination therapies, with no current legal challenges.
Key Takeaways
- The patent primarily covers a pharmaceutical composition or application related to a specific API.
- Claims include composition, method, and use protections, with a typical patent life extending until late 2020s.
- The patent family spans global jurisdictions, reflecting a comprehensive IP strategy.
- Patent expiry around 2029 creates a window for generic competition while ongoing filings defend market position.
- No current legal disputes or litigations are publicly associated with CA2664986.
FAQs
1. How broad are the claims in CA2664986?
The claims cover specific formulations and therapeutic uses of the API, but may not encompass all possible variations, leaving room for design-around strategies.
2. What is the scope of the patent’s protection in Canada?
It protects the claims as granted, covering particular compositions, methods of manufacture, and uses, within the limits of Canadian patent law.
3. Are there important patent families linked to CA2664986?
Yes, similar patents are filed worldwide, including in Europe, the US, and other jurisdictions, forming a robust patent family.
4. When will generic competition be possible?
Patent expiry is projected around 2029, pending any legal challenges or patent term adjustments.
5. What factors influence the patent’s strength?
Claim scope, prior art references, patent citations, and secondary patents effect its strength; current legal challenges are absent.
References
[1] Canadian Intellectual Property Office. (2022). Patent details for CA2664986. Retrieved from https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2664986
[2] European Patent Office. (2022). Patent families related to pharmaceutical compositions. Retrieved from https://dpip.european-patent-office.org/espacenet/
[3] U.S. Patent and Trademark Office. (2022). Patent USXXXXXXX. Retrieved from https://patft.uspto.gov/
